A Fund II company, headquartered in Montreal, Quebec, DalCor is developing precision treatments for cardiovascular disease by genetically targeting patients that will derive clinical benefits.

Domain Therapeutics has a world-leading GPCR target signalling platform, and two lead assets that can overcome checkpoint resistance in different tumors.

A Fund III company headquartered in Quebec and the United Kingdom. Epitopea is a novel platform company aiming to discover cryptic tumor-antigens using a non-traditional approach to develop cancer therapies.

A Fund II company, headquartered in Laval, Quebec, the company’s initial focus is neurological and inflammatory and fibrotic diseases of the airways, liver and gastrointestinal systems.

A Fund III company, headquartered in Barcelona, Ability Pharmaceuticals (Ability Pharma) is a clinical-stage biotherapeutics company developing a novel approach to treating cancer through autophagy.

A Fund II company, headquartered in Vancouver, PHEMI is an Innovative, ground-breaking data privacy solution that enables full data lifecycle management safely and securely.

A Fund II company, headquartered in Toronto, Phenomic AI leverages computer vision and high-content screening to develop therapeutic antibodies against cancer and fibrosis.

A Fund II company, headquartered in Mississauga, Profound is committed to the effort to achieve a new therapeutic standard in prostate cancer. 

A Fund III clinical-stage biotechnology company with operations in Montreal and Boston pioneering novel non-viral genetic medicines.

A Fund II company, headquartered in California, Vaxcyte, Inc. (Vaxcyte) formerly SutroVax, Inc. is a biopharmaceutical company developing vaccines for infectious disease targets with an initial emphasis on best-in-class conjugate vaccines and protein-based vaccines.

A Fund III company headquartered in France. Amolyt Pharma specializes in the development of peptide therapeutics for the treatment rare endocrine and orphan diseases.

A Fund III company headquartered in Montreal, Thryv Therapeutics (Thryv) is a clinical-stage biotherapeutics company developing a first-in-class treatment for cardiovascular diseases.

A Fund I, privately held company, headquartered in Montreal, Enobia Pharma was founded in 1997 and focused on the development of therapies to treat patients with ultra-rare and life-threatening genetic metabolic disorders.

A Fund I company, GLyPharma Therapeutic Inc. (GlyPharma) was a new company created in Montreal for the purpose of a strategic partnership between Ferring Pharmaceuticals (Ferring), a European pharmaceutical company, Fonds de solidarité FTQ and CTI Life Sciences Fund.

A Fund I company, headquartered in Quebec City, Medicago is a clinical-stage biotechnology company focused on developing highly effective and competitive vaccines and therapeutic proteins.

A Fund I, privately held company, headquartered in San Diego, Targegen was founded in 2001. With a mission to use its expertise in vascular biology and knowledge regarding the src kinase to develop drugs in ophthalmology, cancer and inflammatory diseases.

A Fund II company, headquartered in Cambridge, Massachusetts, Visterra was a clinical stage biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases.

A Fund I company, headquartered in Vancouver, Zymeworks is a computational biotechnology company researching and developing next-generation protein therapeutics.

A Fund I and Fund II company, headquartered in Switzerland, VectivBio AG is a late clinical-stage biotechnology company focused on rare conditions with a well-defined biology that can be targeted with transformational therapeutics.